stoxline Quote Chart Rank Option Currency Glossary
  
Vanda Pharmaceuticals Inc. (VNDA)
4.33  -0.04 (-0.92%)    04-17 16:00
Open: 4.34
High: 4.3937
Volume: 502,677
  
Pre. Close: 4.37
Low: 4.3
Market Cap: 253(M)
Technical analysis
2025-04-17 4:53:17 PM
Short term     
Mid term     
Targets 6-month :  5.44 1-year :  6.02
Resists First :  4.65 Second :  5.15
Pivot price 4.32
Supports First :  3.84 Second :  3.2
MAs MA(5) :  4.31 MA(20) :  4.43
MA(100) :  4.65 MA(250) :  4.99
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  55.2 D(3) :  51
RSI RSI(14): 43.3
52-week High :  6.75 Low :  3.84
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VNDA ] has closed below upper band by 49.5%. Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.4 - 4.42 4.42 - 4.44
Low: 4.24 - 4.27 4.27 - 4.3
Close: 4.28 - 4.33 4.33 - 4.37
Company Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Headline News

Mon, 07 Apr 2025
Vanda Pharmaceuticals: Financials Are Great, But Market Reaction Is Confusing (VNDA) - Seeking Alpha

Mon, 07 Apr 2025
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - PR Newswire

Mon, 07 Apr 2025
FDA-Designated Precision Medicine Breakthrough: New Hope for Rare Genetic Disease Patients - Stock Titan

Thu, 03 Apr 2025
Class Action Update Vanda Pharmaceuticals Inc. (VNDA) & Stamps.com Inc. (STMP) - Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire

Tue, 01 Apr 2025
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals - Benzinga

Mon, 31 Mar 2025
Breakthrough Mental Health Drug Seeks FDA Approval for Bipolar and Schizophrenia - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 58 (M)
Shares Float 52 (M)
Held by Insiders 4.6 (%)
Held by Institutions 76.3 (%)
Shares Short 3,560 (K)
Shares Short P.Month 3,720 (K)
Stock Financials
EPS -0.34
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.23
Profit Margin -9.6 %
Operating Margin -19.4 %
Return on Assets (ttm) -4 %
Return on Equity (ttm) -3.5 %
Qtrly Rev. Growth 17.5 %
Gross Profit (p.s.) 3.21
Sales Per Share 3.4
EBITDA (p.s.) -0.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -13.13
PEG Ratio 0
Price to Book value 0.46
Price to Sales 1.27
Price to Cash Flow -16.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android